What are the effects and side effects of tucatinib? What should I pay attention to before use?

Tucatinib, trade name Tukysa, is an oral selective tyrosine kinase inhibitor mainly used to treat HER2-positive advanced or metastatic breast cancer. It inhibits the growth and proliferation of tumor cells by specifically inhibiting the kinase activity of the HER2 (human epidermal growth factor receptor 2) receptor. HER2positive breast cancer refers to overexpression of the HER2 receptor on the surface of breast cancer cells, which is usually resistant to traditional chemotherapy and certain targeted therapies. The emergence of tucatinib provides new treatment options for such patients, especially when patients have shown resistance to previous treatments.

Efficacy

The main effect of Tucatinib is to reduce the proliferation and growth of tumor cells by inhibiting the signaling pathway of the HER2 receptor. It is particularly suitable for patients with HER2-positive breast cancer whose disease has progressed despite traditional treatments (such as chemotherapy, other targeted therapies, etc.). Clinical studies have shown that tucatinib is highly effective in combination therapy, especially when combined with trastuzumab (Herceptin) and pertuzumab (Perjeta). According to a pivotal clinical trial (the HER2CLIMB trial), tucatinib significantly extended progression-free survival (PFS) and overall survival (OS) in patients with HER2 -positive metastatic breast cancer. The results of this trial show that compared with the use of trastuzumab and chemotherapy alone, the combined treatment with tucatinib can effectively control disease progression and improve the survival rate of patients.

side effects

Although tucatinib is an effective targeted therapy, like all drugs, it has certain side effects. Common side effects include:

1.Diarrhea: Diarrhea is one of the most common side effects of tucatinib, and many patients will experience varying degrees of diarrhea during treatment. Severe diarrhea can lead to dehydration and electrolyte imbalance and requires prompt management. Patients should pay attention to fluids and use antidiarrheal medications as recommended by their doctor.

2.Hepatotoxicity: Tucatinib may cause liver function abnormalities, and common liver side effects include elevated transaminases (such asALT, AST) and bilirubin were elevated. Liver function needs to be monitored regularly so that problems can be detected early and the dose can be adjusted or treatment suspended if necessary.

3. Rash: Rash is another common side effect, usually manifesting as mild to moderate skin irritation. In most cases, the rash is mild and can be relieved with topical treatments. However, severe rashes may require treatment to be suspended and medications to be controlled.

4.Fatigue: Patients may experience varying degrees of fatigue during the treatment process, which affects daily life. This side effect is usually temporary, and fatigue may gradually decrease as treatment progresses.

5.Heart problems: Although cardiotoxicity with tucatinib is less common, compared with other HER2 targeted drugs, it is still necessary to pay attention to the monitoring of cardiac function, especially when other drugs that may affect the heart are used together.

6.Nausea and vomiting: Some patients may experience mild nausea and vomiting when taking tucatinib, especially at the beginning of treatment or during medication.

Precautions before use

Before starting tucatinib treatment, patients need a detailed physical examination and examination to ensure they are suitable for use of the drug. Here are some things to note:

1. Liver function test: Since tucatinib may cause liver toxicity, patients should undergo liver function evaluation before treatment to ensure that there is no serious liver dysfunction. Liver function also needs to be monitored regularly during treatment.

2.Heart health: Patients with a history of heart disease need to be cautious when using tucatinib. Although tucatinib has fewer cardiac side effects than other HER2-targeted drugs, patients still need to monitor their heart function, especially when used in combination with other drugs that may affect the heart.

3.Diarrhea management: Since diarrhea is a common side effect during tucatinib treatment, patients need to pay attention to preventing the occurrence of diarrhea during treatment and take timely measures when diarrhea occurs. Doctors may recommend antidiarrheal medications to maintain fluid and electrolyte balance.

4.Drug interactions: Before starting tucatinib treatment, patients should inform their doctors of all drugs they are taking, especially any drugs that may affect liver metabolism (such asCYP3A4 inhibitors or inducers) to avoid drug interactions. Tucatinib may interact with some drugs, affecting their metabolism or efficacy.

5. Pregnancy and breastfeeding: Tucatinib may have adverse effects on the fetus, so pregnant women or women planning to become pregnant should avoid using this drug. For women who are breastfeeding, it is recommended to discontinue breastfeeding while taking tucatinib.

Tucatinib (Tucatinib) is a drug that targets HER2Effective therapeutic drugs for positive advanced breast cancer can significantly improve patient survival rates and disease control. However, patients need to be aware of possible side effects when using tucatinib, especially diarrhea, liver toxicity, and rash. Before use, patients should undergo a comprehensive physical examination and closely monitor the side effects of the drug during treatment to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.tukysa.com/